CALCAGNO, Andrea
 Distribuzione geografica
Continente #
NA - Nord America 15.653
EU - Europa 9.202
AS - Asia 3.556
SA - Sud America 394
AF - Africa 341
OC - Oceania 118
Continente sconosciuto - Info sul continente non disponibili 24
Totale 29.288
Nazione #
US - Stati Uniti d'America 15.338
IT - Italia 2.026
CN - Cina 1.851
DK - Danimarca 1.383
IE - Irlanda 990
SE - Svezia 743
FR - Francia 707
DE - Germania 638
GB - Regno Unito 519
FI - Finlandia 432
UA - Ucraina 325
AT - Austria 300
KR - Corea 270
VN - Vietnam 254
IN - India 238
PL - Polonia 227
ES - Italia 209
CA - Canada 204
NL - Olanda 200
BR - Brasile 188
SG - Singapore 171
JP - Giappone 167
ZA - Sudafrica 122
ID - Indonesia 112
AU - Australia 107
RO - Romania 95
MX - Messico 84
TW - Taiwan 83
BE - Belgio 81
RU - Federazione Russa 81
TH - Thailandia 80
CH - Svizzera 71
HK - Hong Kong 70
TR - Turchia 61
AR - Argentina 59
CO - Colombia 49
PK - Pakistan 44
CL - Cile 41
IR - Iran 35
PE - Perù 35
GR - Grecia 31
PT - Portogallo 31
PH - Filippine 26
UG - Uganda 25
NG - Nigeria 22
EU - Europa 21
IL - Israele 18
KE - Kenya 18
EG - Egitto 17
ET - Etiopia 16
TZ - Tanzania 16
NO - Norvegia 14
CZ - Repubblica Ceca 13
MY - Malesia 13
HR - Croazia 12
HU - Ungheria 12
BG - Bulgaria 11
EC - Ecuador 11
NZ - Nuova Zelanda 11
SA - Arabia Saudita 11
SK - Slovacchia (Repubblica Slovacca) 11
SN - Senegal 11
MW - Malawi 10
ML - Mali 9
SD - Sudan 9
DZ - Algeria 8
TN - Tunisia 8
UZ - Uzbekistan 8
AE - Emirati Arabi Uniti 7
GM - Gambi 7
MU - Mauritius 7
BY - Bielorussia 5
JO - Giordania 5
LU - Lussemburgo 5
LV - Lettonia 5
RS - Serbia 5
BO - Bolivia 4
CR - Costa Rica 4
CU - Cuba 4
EE - Estonia 4
GA - Gabon 4
GH - Ghana 4
HN - Honduras 4
KZ - Kazakistan 4
MD - Moldavia 4
MZ - Mozambico 4
PA - Panama 4
BH - Bahrain 3
CD - Congo 3
CM - Camerun 3
DO - Repubblica Dominicana 3
GE - Georgia 3
GT - Guatemala 3
LT - Lituania 3
MA - Marocco 3
MO - Macao, regione amministrativa speciale della Cina 3
PR - Porto Rico 3
VE - Venezuela 3
ZW - Zimbabwe 3
AL - Albania 2
Totale 29.241
Città #
Ann Arbor 2.899
Chandler 1.715
Beijing 1.068
Dublin 982
Fairfield 971
Houston 659
Ashburn 642
Wilmington 560
Torino 539
Woodbridge 475
Redwood City 394
Villeurbanne 394
Seattle 376
Dearborn 344
Medford 341
Princeton 311
Nyköping 307
Cambridge 298
Jacksonville 294
Vienna 244
Pisa 227
Warsaw 209
Fremont 186
Turin 151
Milan 137
Dong Ket 125
New York 119
Singapore 108
Boston 99
San Diego 90
Shanghai 77
Guangzhou 74
Hangzhou 67
Boardman 60
Paris 60
Toronto 59
Nanjing 58
Brussels 56
Helsinki 55
Washington 55
Taipei 53
Rome 49
Ottawa 44
São Paulo 44
Phoenix 43
Hebei 42
Kunming 39
Seoul 39
Verona 39
Chicago 38
Los Angeles 37
Norwalk 37
London 36
Cape Town 34
Santiago 34
Hefei 33
Jakarta 33
Barcelona 32
Chengdu 32
Munich 32
Buenos Aires 29
Silver Spring 29
Lima 28
Tokyo 26
Falls Church 25
Upper Marlboro 25
Amsterdam 24
Hong Kong 23
Omaha 23
Central District 22
Hanoi 22
Arlington 21
Bengaluru 21
Buffalo 21
Montreal 21
Dallas 20
Melbourne 20
Duncan 19
Pune 19
Copenhagen 18
Frankfurt am Main 18
Montréal 18
Mountain View 18
Mumbai 18
Tariceni 18
Toulouse 18
Brescia 17
Jinan 17
Wuhan 17
Atlanta 16
Changsha 16
Nanchang 16
Bangkok 15
Madrid 15
Mexico 15
Nürnberg 15
Sydney 15
Baltimore 14
Fuzhou 14
Istanbul 14
Totale 17.435
Nome #
Pharmacokinetics and pharmacogenetics of anti-tubercular drugs: a tool for treatment optimization? 770
Pharmacokinetics and pharmacodynamics of antiretrovirals in the central nervous system. 692
Cytomegalovirus central nervous system compartmentalization in a patient presenting with AIDS 581
Cardiac dysfunction in pauci symptomatic human immunodeficiency virus patients: a meta-analysis in the highly active antiretroviral therapy era 469
TB and COVID-19 co-infection: Rationale and aims of a global study 418
Antiretroviral therapy in geriatric HIV patients: The GEPPO cohort study 397
The outcome of HIV-positive late presenters according to detectable CMV DNA and anti-CMV treatment 392
High prevalence at computed coronary tomography of non-calcified plaques in asymptomatic HIV patients treated with HAART: A meta-analysis 364
Cerebrospinal Fluid Inhibitory Quotients of Antiretroviral Drugs in HIV-positive Patients are Associated with Compartmental Viral Control. 356
Elvitegravir/Cobicistat/Tenofovir/Emtricitabine Penetration in the Cerebrospinal Fluid of Three HIV-Positive Patients 339
Effect of SNPs in human ABCB1 on daptomycin pharmacokinetics in Caucasian patients. 330
High interpatient variability of raltegravir CSF concentrations in HIV-positive patients: a pharmacogenetic analysis. 307
Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms. 299
Prevalence and predictors of long corrected QT interval in HIV-positive patients: a multicenter study 298
A UPLC-MS-MS method for the simultaneous quantification of first-line antituberculars in plasma and in PBMCs 293
Heart failure in patients with human immunodeficiency virus: a review of the literature. 292
HIV-1 Very Low Level Viremia is Associated with Virological Failure in HAART-treated Patients 280
Tenofovir coadministration is not associated with lower unboosted atazanavir plasma exposure in the clinical setting 277
Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatment. 275
Tenofovir clearance is reduced in hiv-positive patients with subclinical tubular impairment 264
Raltegravir penetration in seminal plasma of healthy volunteers. 247
CNS-Targeted Antiretroviral Strategies: When Are They Needed and What to Choose 242
Intracellular accumulation of ritonavir combined with different protease inhibitors and correlations between concentrations in plasma and peripheral blood mononuclear cells. 235
Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study) 234
Single-nucleotide polymorphisms ABCB1 3435C>T, 1236C>T and CYP2B6 516G>T influence plasma concentrations of Efavirenz (EFV). 227
Health-care Associated KPC-BSI: The Time Has Come. 226
Presence of EBV DNA in Cerebrospinal Fluid is Associated with Greater HIV RNA and Inflammation 212
Lower dolutegravir plasma concentrations in HIV-positive patients receiving valproic acid 208
SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV 202
Pharmacogenetics of Antiretrovirals' Penetrations into Cerebrospinal Fluid 200
Prevalence and predictors of blood-brain barrier damage in the HAART era. 195
Acute HIV infection: Improved algorithms for HIV testing. 194
SLC28A2 65C>T predict Sustained Virological Response in patients with hepatitis C treated with interferon and ribavirin, considering all HCV genotype and genotype 1/4. 192
Anti-CD20 antibody therapy for B-cell lymphomas 188
Cerebrospinal fluid viral load and neopterin in HIV-positive patients with undetectable viraemia 180
Pharmacogenetic determinants of kidney-associated urinary and serum abnormalities in antiretroviral-treated HIV-positive patients 176
Tipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimens 174
Elimination half-life may explain the relative efficacy of boceprevir and telaprevir in the treatment of hepatitis C virus genotype 1. 174
Could ritonavir intracellular concentrations have a role as active drugs when used as a booster PIs? 173
Cardiovascular disease in HIV patients: from bench to bedside and backwards 172
SLC29A1 −706G>C predict haemoglobin decrease in patients with hepatitis C treated with interferon and ribavirin 171
Effect of Darunavir (DRV) genotypic inhibitory quotient (gIQ) on the virological response to DRV-containing salvage regimens at 24 weeks 168
Clinical pharmacology of tenofovir clearance: a pharmacokinetic/pharmacogenetic study on plasma and urines 162
A population pharmacokinetic model confirms an association between a pregnane-X-receptor (PXR) polymorphism and unboosted atazanavir clearance 160
Etravirine Plasma Exposure is Associated with Virological Efficacy in Treatment-experienced HIV-positive Patients. 160
TENOFOVIR AND EMTRICITABINE CSF-TO-PLASMA RATIOS CORRELATE TO THE EXTENT OF BLOOD BRAIN-BARRIER DAMAGE 160
Efficacy, safety and pharmacokinetics of atazanavir (200mg twice daily) plus raltegravir (400mg twice daily) dual regimen in the clinical setting 158
In-hospital and long-term outcomes of HIV-positive patients undergoing PCI according to kind of stent: a meta-analysis 156
Analysis of determinants of long-term efficacy of unboosted atazanavir-based regimens in the clinical setting 155
Pharmacokinetics of 400 mg of raltegravir once daily in combination with atazanavir/ritonavir plus two nucleoside/nucleotide reverse transcriptase inhibitors. 154
The Influence of Pharmacogenetic Variants in HIV/Tuberculosis Co-infected Patients in Uganda in the SOUTH Study 154
Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics. 153
A(H1N1)pdm09 hemagglutinin D222G and D222N variants are frequently harbored by patients requiring extracorporeal membrane oxygenation and advanced respiratory assistance for severe A(H1N1)pdm09 infection 152
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update December 2014 152
INTRACELLULAR ACCUMULATION OF RITONAVIR ASSOCIATED WITH DIFFERENT BOOSTED PIS 152
Ribavirin pharmacokinetics and interleukin 28B plus cytochrome P450 27B1 single-nucleotide polymorphisms as predictors of response to pegylated interferon/ribavirin treatment in patients infected with hepatitis C virus genotype 1/4. 151
Viral rebound after switch to maraviroc/raltegravir dual therapy in highly experienced and virologically suppressed patients with HIV-1 infection. 151
Tenofovir and emtricitabine cerebrospinal fluid-to-plasma ratios correlate to the extent of blood-brainbarrier damage. 148
A filter-based cross-sectional analysis of an HIV-positive, HAART-treated cohort in rural Burundi: pharmacokinetics, pharmacogenetics and viral load 147
Plasma and Intracellular Imatinib Concentrations in Patients With Chronic Myeloid Leukemia 147
Determinants of Tenofovir Plasma Trough Concentrations: a Cross-sectional Analysis in the Clinical Setting 147
Clinical pharmacology of complex regiment of antiretroviral therapy including Etravirine, Maraviroc and Raltégravir. 146
Tenofovir Plasma Concentrations According to Companion Drugs: a Cross-sectional Study in HIV-positive Patients with Normal Renal Function. 145
Single-nucleotide polymorphism PXR 7635G>A influences plasma concentrations of Efavirenz in CYP2B6 516G>T carriers 145
Undetectable Ritonavir Plasma Concentrations in Different Boosted PI-based Regimens as a Marker of Non-Adherence: analysis of a large TDM Registry 144
What do we know about tailoring treatment with tenofovir? 144
Symptomatic cerebrospinal fluid HIV-1 escape with no resistance-associated mutations following low-level plasma viremia 144
Detectable cerebrospinal fluid JCV DNA in late-presenting HIV-positive patients: beyond progressive multifocal leukoencephalopathy? 144
Pharmacokinetic Determinants of Immunovirological Response in HIV Very Late Presenters 142
Pharmacokinetics of switching unboosted atazanavir coadministered with tenofovir disoproxil fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients. 142
Pharmacokinetic and pharmacodynamic determinants of early virological response to enfuvirtide-based regimens in HIV-positive patients 140
Efficacy, Safety and Pharmacokinetics of Atazanavir (200 mg twice-daily) plus Raltegravir (400 mg twice-daily) Dual Regimen in the Clinical Setting 140
Pharmacokinetics of Raltegravir, Etravirine and Maraviroc regimen in the clinical setting 140
Viral rebound after switch to Maraviroc-Raltegravir dual therapy 139
MONITORING OF VIROLOGICAL AND PHARMACOLOGICAL CEREBROSPINAL FLUID PARAMETERS IN HAART-TREATED HIV-POSITIVE PATIENTS IN THE CLINICAL SETTING 139
Clinically significant drug interaction between tipranavir-ritonavir and phenobarbital in an HIV-infected subject 138
Intracellular accumulation of the new integrase inhibitors elvitegravir and dolutegravir in HIV patients 137
Comparative evaluation of seven resistance interpretation algorithms and their derived genotypic inhibitory quotients for the prediction of 48 week virological response to darunavir-based salvage regimens. 137
Tuberculosis and COVID-19 co-infection: description of the global cohort 137
Pharmacokinetics of the Dual NRTI- and Protease Inhibitor-sparing Regimen Raltegravir plus Nevirapine in HIV-1+ Patients 136
Antiretroviral Drug Penetration into the CNS Compartment 136
Steady-state Raltegravir Penetration in Seminal Plasma of Healthy Volunteers 135
Louseborne relapsing fever among East African refugees, Italy, 2015 135
GREATER IMMUNOLOGICAL RECOVERY ASSOCIATED WITH ADDITIONAL ENFUVIRTIDE IN THE TREATMENT OF NAIVE HIV-INFECTED PATIENTS AT VERY ADVANCED DISEASE STAGES: 24-WEEK RESULTS OF A RANDOMIZED, CONTROLLED, PILOT STUDY 135
Short-term additional enfuvirtide therapy is associated with a greater immunological recovery in HIV very late presenters: a controlled pilot study. 133
High Interpatient Variability of Raltegravir Cerebrospinal Fluid Concentrations in HIV-positive Patients: a Pharmacogenetic Analysis 133
Role of vitamin D pathway gene polymorphisms on rifampicin plasma and intracellular pharmacokinetics 131
High incidence of infections in HIV-positive patients treated for lymphoproliferative disorders 130
Comparative safety and efficacy of statins for primary prevention in human immunodeficiency virus-positive patients: a systematic review and meta-analysis 128
Dual antiretroviral therapies are effective and safe regimens in the central nervous system of neurologically symptomatic people living with HIV 128
Is Maraviroc a substrate for SLCO1B1? 127
Is peritoneal fluid a sanctuary site for HIV? 127
Intracellular Pharmacokinetics of Boosted and Unboosted Atazanavir in HIV Infected Patients 127
Seminal pharmacokinetics and antiviral efficacy of once-daily maraviroc plus lopinavir/ritonavir in HIV-infected patients. 127
Genetic Polymorphisms Affecting the Pharmacokinetics of Antiretroviral Drugs 125
Etravirine Plasma Exposure is Associated with virological Response in Experienced HIV-positive Patients 124
Pharmacokinetics of the raltegravir/maraviroc/etravirine combination. 122
The symptomatology of cerebrospinal fluid HIV RNA escape: a large case-series 122
Disappearance of Renal Stones in an HIV-1-Infected Patient After Reduction of Atazanavir Dose. 119
Medication Burden and Clustering in People Living with HIV Undergoing Therapeutic Drug Monitoring 119
Totale 20.244
Categoria #
all - tutte 74.617
article - articoli 0
book - libri 0
conference - conferenze 13.086
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 87.703


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019964 0 0 0 0 0 0 0 0 0 0 638 326
2019/20205.318 221 194 206 534 531 859 483 357 344 461 512 616
2020/20213.619 459 197 189 210 295 314 246 153 312 291 272 681
2021/20226.028 481 414 510 578 448 451 543 496 376 276 746 709
2022/20235.490 525 409 153 509 515 1.333 375 390 591 147 302 241
2023/20242.449 337 423 181 153 229 385 103 173 59 160 246 0
Totale 30.692